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Abstract
Human embryonic stem cells (hESCs) have been extensively discussed in public and scientific
communities for their potential in treating diseases and injuries. However, not much has been
achieved in turning them into safe therapeutic agents. The hurdles in transforming hESCs to
therapies start right with the way these cells are derived and maintained in the laboratory, and goes
up-to clinical complications related to need for patient specific cell lines, gender specific aspects,
age of the cells, and several post transplantation uncertainties. The different types of cells derived
through directed differentiation of hESC and used successfully in animal disease and injury models
are described briefly. This review gives a brief outlook on the present and the future of hESC based
therapies, and talks about the technological advances required for a safe transition from laboratory
to clinic.
1. Introduction
Biomedical research using embryonic stem cells (ESC) is a
very promising area for the investigation of the possibili-
ties of developing newer cell replacement therapies
(CRTs). Diseases and disorders which have no therapy or
at best partially effective ones mainly attract the pursuit of
ESC research. The first ESC line was established from
mouse embryos in 1981 [1], following a method virtually
identical to rabbit models used by Cole RJ et al., [2] about
30 years earlier. These ESCs have been used for introduc-
ing specific gene modifications in mice. Sir Martin Evans
has recently been honored with the Nobel Prize for Phys-
iology and Medicine (2007) for his contribution towards
development of animal models of disease through ESC
mediated gene targeting. Human embryonic stem cells
were first derived by Thompson's group in 1998 [3] and
are usually derived from the inner cell mass (ICM) of blas-
tocyst stage embryos that are left over after in vitro fertili-
zation (IVF) and after embryo donations [4]. The
derivation of hESCs have opened up huge possibilities for
regeneration and repair of organs of tissues and thus been
envisioned as therapeutic agents.
"Self-renewal" i.e., the ability to undergo indefinite self-
renewing and symmetric cell divisions to maintain the
population, and "pluripotency" which indicates their
ability to differentiate into any of the 200 different known
cell types (of ectoderm, endoderm, mesoderm and troph-
ectoderm lineages); are the two hallmarks of these cells
[5]. Though these are the key properties of the hESCs, yet
they are not a property of the ICM in vivo and must be a
characteristic adopted by the cells during their initial out-
growth in the culture. The use of human embryonic stem
cells (hESCs) in cell replacement therapies (CRTs) has
been limited due to several technical and ethical issues.
Since its inception there has been an extensive debate
about the benefits and drawbacks of adult vs hESC use in
therapies [6,7]. For hESCs the problems range from the
way they are derived, characterized, established and main-
tained, to their in-vitro differentiation and transplanta-
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tion. Changes in their epigenetic profiles, chromosomal
aberrations during their establishment and maintenance,
post transplantation challenges like risk of tumors, genetic
instability, and immune-rejections are some of the other
major concerns.
ESC-like cells have also been derived from mouse skin
cells [7]. ESC lines have also been established from single
cell biopsies of a developing embryo [8,9]. Such advances
if successfully reproduced in human, could possibly
demolish the ethical objections related to destroying a
potential life that has haunted the field for many years.
This review presents a generalized opinion and outlook
on the alternative strategies required to develop effective
and novel hESCs based therapies.
2. Barriers to bringing hESCs to clinic
Seven major concerns identified as significant roadblocks
to the safe transition of hESC to clinic are discussed in the
following subsections.
2.1 Derivation of hESCs: need for "Embryo-friendly" ways
Destruction of life in the form of an embryo has been a
major ethical objection in embryonic stem cell derivation
and research in several western countries. One way to get
around this objection will be to generate human ESC lines
without the use of additional human embryos. The differ-
ent approaches suggested so far are discussed below:
a) Reprogramming of adult cell nucleus
The method uses existing hESCs to fuse with an adult
somatic cell, generating a cell line that retains ESC specific
properties and yet has the genotype of the somatic cell
donor [10]. However, there is no technology available to
selectively remove all the ESC chromosomes while retain-
ing the somatic cell chromosomes. In addition this
removal of chromosome needs to be timed to occur only
after the hybrid cell has been reprogrammed to take the
properties of the stem cells. Development of such technol-
ogies is potentially expensive and will presumably take
years.
b) ESCs from embryo like entities
This approach involves the use of somatic cell nuclear
transfer (SCNT) to produce developmentally compro-
mised embryo-like structures, with the help of genetically
premodified deficient nuclei which cannot support devel-
opment [11]. The zygote produced by such nuclear trans-
fer undergoes cleavage in-vitro and produce ICM cells,
which would be used for deriving ESCs, but would not
proceed further in development. A proof of principle to
this was accomplished by generating mouse ESCs, using a
donor nucleus which was silenced for Cdx2 gene [12].
This is ethically correct for those who believe that fetal life
begins only after the embryo implants. However, one
need not go for creating a mutation to achieve this target,
as a blastocyst cannot develop into a complete human life
in vitro, irrespective of the presence or absence of any kind
of genetic alterations.
c) ESC lines from single blastomeres
It is known that if a cell or two is missing from a preim-
plantation embryo it can regenerate the missing part and
form a whole embryo. A single cell can be isolated from
the cleavage stage embryo, a technique well established
for preimplantation genetic diagnosis (PGDs), and used
to create a cell line from it; the rest of the embryo can be
transferred back to the uterus to give rise to a fetus [8].
Robert Lanza's group has shown that ESC lines could be
established from single cell biopsies of the mouse and
human embryos [8,9]. However, this technique is very dif-
ficult to translate to human being. Also, the fate of the
residual embryos if they are transferred is largely
unknown, as there is a lack of long term studies support-
ing the health of babies born following PGD.
d) ESC lines from induced somatic cell dedifferentiation
In this method the adult somatic cells are genetically
modified and reprogrammed to undergo a process of ded-
ifferentiation, by inducing the expression of pluripotency
related genes. Recently, induced pluripotent stem cell
lines have been derived by allowing trans-acting factors
present in the mammalian oocytes to reprogram somatic
cell nuclei to an undifferentiated state [13]. They have
demonstrated that four factors OCT-4, SOX-2, Nanog and
LIN28 are sufficient to reprogram human somatic stem
cells to pluripotent stem cells. Whereas, Takahashi and
Yamanaka (2006) induced somatic cells into pluripotent
stem cells by introducing four factors OCT-4, SOX-2, c-
Myc and KLF-4. These cells designated as induced pluripo-
tent stem cells (iPS) exhibit morphology of embryonic
stem cells and express ES cell markers [14]. Although,
Takahashi and Yamanaka (2006) and Yu et al., (2007)
carried out astonishing experiments by reprogramming
somatic cells into pluripotent stem cells, several technical
limitations such as use of retrovirus or lentiviruses for
transfecting OCT-4, Nanog, SOX-2, C-MYC, LIN28 or
KLF4 restrict the use of such cell lines for clinical applica-
tions [15] (Hanna et al., 2007).
e) Embryonic like stem cells from alternative sources
Adult stem cells similar to blastomeres of the preimplan-
tation stage embryos have been identified and isolated by
Henry Young and coworkers [16]. These cells called the
blastomere-like stem cells (BLSCs) are found to be totipo-
tent due to their potential to give rise to all tissue types
including the gametes. These BLSCs can be induced to dif-
ferentiate in a unidirectional manner to form pluripotent
embryonic-like stem cells (ELSCs). It is also claimed that
these cells do not express the MHC class-I or HLA DR-IIJournal of Translational Medicine 2008, 6:7 http://www.translational-medicine.com/content/6/1/7
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cell surface markers. More recently Meng et al., (2007)
have discovered a population of stem cells in the men-
strual blood [17]. These cells named as the "Emdometrial
Regenerative Cells" are shown to be capable of differenti-
ating into 9 tissue lineages namely: cadiomyocytic, respi-
ratory epithelial, neurocytic, myocytic, endothelial,
pancreatic, hepatic, adipocytic, and osteogenic.
2.2 Need for xeno-free culture systems
Conventionally, human embryonic stem cell lines are
grown 1) in a medium containing animal serum as a
source of nutrients and growth factors and 2) on mouse-
derived fibroblast as feeder layers, which play a role in the
proliferation and inhibition of their differentiation. How-
ever, the use of any cell based therapeutic agent in human
must be free of animal contaminations which may con-
tain certain pathogens or xenogens that can trigger
immune reactions after transfer to a host. Some laborato-
ries have successfully cultured hESC in a serum-free
defined medium on human cell-derived feeders or even in
feeder free conditions [18 19]. Another significant
achievement in this context was the derivation and estab-
lishment of a hESC line under animal product free condi-
tion [20].
Expression of a nonhuman sialic acid Neu5Gc and pres-
ence of murine viruses are two concerns in existing hESCs
grown in presence of animal products or feeders [21].
Replacement of animal serum with human serum has
been reported to reduce the expression of Neu5Gc in the
hESCs, also Amit et al (2005) have reported the absence
of murine leukemia virus in a number of hESC lines main-
tained on mouse feeders [22]. These studies are largely
indicative of the fact that the problem of animal product
contamination in the existing culture would be possibly
solved in the near future.
2.3 Risk of tumors
Following transplantation hES cell based therapies
involves the risk of tumor formation arising from undif-
ferentiated population of the transplanted cells. Studies
with both ESCs and ES derived differentiated cells have
shown that they can form teratocarcinomas in adult mice
if injected subcutaneously, intramuscularly or into the tes-
tis [5,8,23,24]. It has also not been possible to produce a
pure population of more that 80% of differentiated cells
from mouse or human ESCs using any of the directed dif-
ferentiation protocols. In a cell culture for therapeutic use,
the presence of even one undifferentiated cell may poten-
tially lead to teratomas, a cancerous tumor which is
derived from germ cells and can from all the three germ
layers.
One way of obtaining a pure culture of differentiated cells
would be to confirm a negative expression for Oct4 or
Nanog in them. Also new strategies can be developed
which in some way would tag the ESC implants that could
accidentally forms tumors, with death or suicide signals
[25]. Alternatively, ESCs can be genetically engineered so
that a negative selection can be carried out based on a
compound that is toxic to undifferentiated ESCs under
certain culture conditions [26]. Studies with mouse ESC
show that if a more differentiated cell population is used
for grafting, the cells are less likely to generate a tumor
[27]. A differentiated population of cells can be segregated
from a mixed cell population using either a technique like
Fluorescence Activated Cell Sorting (FACS) or other selec-
tive approaches [28,29]. Bieberich et al., (2004) showed
that treating the mixed population with the ceramide ana-
logue N-oleoyl serinol (S18) can selectively induce apop-
tosis of ESCs [30]. While adequate technologies for
screening and generating a pure population of differenti-
ated stem cells are available, it is yet not known whether
they are capable of eliminating each and every potential
tumor forming ES cell.
2.4 Genetic instability
Questions on the suitability of ESCs for transplantation
purpose is raised because of the observed genetic instabil-
ity of cloned cells and extreme inefficiency of the process
[31]. Cloned animals like Dolly give the outward appear-
ance of full health, but the probability of their having
numerous genetic defects is very high. Hochedlinger and
Rudolf Jaenisch (2002) showed that in mice, cloned using
ESC in place of the somatic cells (which produces better
results) the reprogramming of the inserted genetic mate-
rial by the embryonic cells proceeded in a very unregu-
lated way [32]. They reported that many of the genes that
are necessary for the early phase of embryonic develop-
ment were not activated.
2.5 Transplant rejection
The immune system tends to reject the transplanted ESCs
as 'foreign'. This rejection can be inhibited by the use of
immunosuppressive drugs which can have serious side
effects. Alternate approaches using homolologous recom-
bination techniques can allow the host immune system to
recognize and mark the ESCs as 'self'. This is possible by
replacing the MHC genes in ESCs with the host MHC
genes [33]. Elimination of MHC class I and II gene loci is
also proposed, though this would be technically challeng-
ing and would be clinically problematic because cells
lacking MHC class I surface expression are targeted by NK
cells [34,35].
One possible alternative is to establish a bank of MHC-
compatible hESC lines. Taylor et al., (2005) reported that
a reasonable HLA match for around 85% of the UK popu-
lation could be achieved with around 150 lines [36].
However, this number might be conservative for countriesJournal of Translational Medicine 2008, 6:7 http://www.translational-medicine.com/content/6/1/7
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like India and the USA, which have a varied and multi-
racial population [37]. Even with such banks in most
cases immunosuppressive drugs would still be needed for
most donor patient combinations. Some also believe that
the transplantation of hESC derivatives into immune-
privileged sites such as the brain, say to treat Parkinson's
disease, may possibly ameliorate the adverse effects of a
MHC-mismatch, although the protection would only be
short term.
A possible way to overcome immune rejection is to over
express genes that can suppress the immune system such
as fas-ligand into ES cells [38]. It is suggested that removal
of certain cell surface molecules like B7 antigens or CD40
ligands that are immunologically reactive from ES cells
prior to transplantation could suppress immune rejec-
tions. For this, somatic cell nucleus from the recipient/
patient can be subjected to such genetic modifications
and can be inserted into an enucleated oocyte. Though
this technology would help in developing patient specific
ESCs lines, it would also carry along with it several ethical
and technical limitations [32]. As in most incurables dis-
eases, if the patient is suffering from a degenerative condi-
tion which destroys their own cells, the transplanted ESCs
will suffer the same fate. Therefore in such cases trans-
planting a population of cells that includes a proliferating
progenitor is needed to provide a continuous source of
differentiating cells. Again as discussed earlier these trans-
plants might run the risk of tumor formation.
2.6 Epigenetic reprogramming and culture adaptation
HESC lines can differ from each other in their genomic
expression profiles through epigenetic regulations. Two
major causes for epigenetic changes in hESCs have been
identified; 1) the epigenetic changes in preimplantation
embryos used for derivation of the hES cell lines, and 2)
epigenetic changes during their maintenance in the cul-
ture over time.
Epigenetic changes in embryos
In the preimplantation embryos epigenetic modifications
such as DNA methylation and histone modifications are
widely involved in the regulation of imprinted and non-
imprinted genes. These events are often vulnerable to the
external environment or culture conditions. Ericson and
Kallen, (2001) have reported the occurrences of congeni-
tal malformations after the use of assisted reproductive
technologies (ART) in human [39]. ART has also been
linked to imprinting disorders, such as Beckwith-Wiede-
mann Syndrome and Angelman Syndrome (AS) [40,41].
It has been shown that these disorders result from
hypomethylation of the maternal genome [42,43]. A set
of a few such methylated and imprinted genes like TSSC5,
H19, PEG1, SNRPN, Xist, Oct4, Notch1, DLK1 etc., are
now being studied for their methylation status as a part of
the characterization process for new hESC lines [44].
More elaborate studies on various existing hESC lines are
required to identify the epigenetic markers for pluripo-
tency. Most existing hESC lines have been established
under different culture conditions, this might cause varia-
tions in epigenetic profiles over and above that inherited
from in-vitro production of the embryo [45].
Epigenetic changes over time
Human ESCs can be used as suitable models for genetic
defects, diseases, drug screening and cell replacement
therapies only if they are genetically stable over long peri-
ods in culture. However, a recent report by Allergrucci et
al., (2007), shows that hESCs can undergo epigenetic
changes over time in culture [46]. They found maximum
changes in the epigenetic profile of these cells at the early
stages post derivation and after growing them in serum
free culture systems [47]. In another report a DNA meth-
ylation profile for hESC was determined, and a set of 25
sites from 23 genes were also identified, which could dis-
tinguish normal hESCs from differentiated cells [48].
Lagarkowa et al., (2006) demonstrated that the methyla-
tion status of pluripotency genes like DPPA3 and DPPA5
varied between hESC lines and also during their differen-
tiation into embryoid bodies [49]. All these studies indi-
cate the need for optimization of procedures that would
minimize culture-induced genomic instability. This also
implies that periodic monitoring of these lines will be
required to evaluate their suitability for in-vivo applica-
tions. It is possible that hESCs can get rapidly repro-
grammed into unpredictable genetic changes and that
some existing and late-passage hESC lines may not be
suitable for therapeutic uses.
2.7 Chromosomal abnormalities during prolonged culture
Selection and adaptation of hESCs is a poorly understood
phenomenon. An extreme variability in culture condi-
tions exist not only between labs, but even within labora-
tories. The establishment and maintenance of these cells
must involve some form of 'culture adaptation' process,
most like epigenetic in nature as discussed above. How-
ever, several reports also indicate that these cells acquire
chromosomal abnormalities or karyotype aberrations
during prolonged culture in parallel with epigenetic
changes [50]. Such adaptations may result in enhanced
cloning efficiencies after plating single cells [51], a
reduced tendency for apoptosis [52], and is expected to
have a reduced capacity for differentiation which is diffi-
cult to assess quantitatively. A recent report by Baker et al.,
(2007) demonstrates clear evidence for the accumulation
of specific chromosomal aberrations within several well-
established hESC lines over time [53]. Results from previ-
ously published data were pooled and compared with
their own data to access the temporal affects of long term
in vitro maintenance on the genetic stability of hESC lines.Journal of Translational Medicine 2008, 6:7 http://www.translational-medicine.com/content/6/1/7
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The study indicates that hESCs indeed become chromo-
somally abnormal and 'culture adapted' in a reproducible,
non-random nature over time. They also found a bias for
gains in chromosomes 12, 17, and X, which are similar to
chromosomal change seen in breast cancer and testicular
germ cell tumor (TGCT) seminomas and non-semino-
mas. This indicates that these chromosomal regions may
harbor replication dependent genes critical for cell prolif-
eration. Interestingly, antiapoptotic genes like BIRC5;
pluripotency genes like NANOG, DPPA3, and GDF3; cell-
cycle regulator like CCND2; and other genes involved in
cancer tumorigenesis like TGCT1, KRAS and SOX5, lie in
chromosome 17, chromosome 12, and the X chromo-
some [53]. With all these evidences it is becoming increas-
ingly clear that standard immuno-markers commonly
employed to identify hESCs are not adequate to demon-
strate that the hESCs are normal.
3. Embryonic stem cell based therapies: 
advances
What may have appeared to be impossible with ESC
research several years ago is gradually turning into reality.
Scientists are trying to coax the ES cells to differentiated
population of cells which could be used for therapies. For
a list of in vitro differentiated cell types derived from
hESCs by various groups please refer to Deb et al., (2007)
[54]. A list of preclinical animal models where human
ESCs have demonstrated efficiency is listed in Table 1.
Besides this scientists are trying to use ESCs for various
other applications. For example, the use of ESCs as vehi-
cles for tropic support for dying neurons is possibly a
more feasible goal and many workers are focusing on this
kind of studies [41]. Efforts are being made to use this
technology, to modify the ESCs for use in delivery of
genes and other factors to dying motor neurons.
Generation of patient specific human nuclear transfer ESC
(hNT-ESCs) lines is a strategy that may circumvent the
problem of immuno-rejection which is the greatest chal-
lenge in CRTs [55]. The implications of transferring mito-
chondrial hetroplasmic cells, which might contain
aberrant epigenetic gene expression profiles, are also of
concern. Allogenic mitochondria present in the NT-ESC
derived cells could be recognized by the host immune sys-
tem, leading to disrupted mitochondrial membrane
potential that induces apoptosis [52,56]. The mitochon-
drial genome is also known to encode a number of trans-
plantation antigens that could trigger a immune response
for the host tissue following engraftment [57], for exam-
ple the maternally transmitted mtDNA-encoded minor
histocompatibility antigen (mi-Has) [58,59]. This has
been demonstrated in failed cardiomyocyte grafts with
mitocondria induced apoptosis in a rat model [60].
Pathenogenetically activated embryos has been proposed
for the creation of female haploid ESC lines. These cells
could serve as an autologous source of cells for producing
differentiated cell types to treat women suffering from dis-
eases like Type 1 diabetes or spinal cord injuries [61]. This
possibility has been tested in a primate model [62]. How-
ever, it is not know if a differentiated haploid cell type fol-
lowing a transplant would remain normal in-vivo.
Recently Revazova et al., (2007) has reported the develop-
ment of six patient specific stem cell lines from partheno-
genetic blastocysts [63]. They have also used a protocol
which minimizes the use of animal derived components
Table 1: A list of animal injury and disease models where hESCs have been shown to be effective
CELL TYPE DEVELOPED ANIMAL MODEL REFERENCE
Oligodenrocyte progenitor Spinal cord injury induced mouse Keirstead et al., 2005 [69]; Nakamura et al., 
2005 [70]
Cardiomyocytes Rat, Swine, Mice Laflamme et al., 2007 [71]; Leor et al., 1996 
[72]; Kehat et al., 2004 [73]; Caspi et al., 2007 
[74]
Hepatocyte CCl4-injured SCID mouse model Seo et al., 2005 [75]
Chondrocyte Canine Spinal Fusion model Muschler et al., 2003 [76]
Endothelial cells Surgical induction of hind limb ischemia in 
athymic mouse
Cho et al., 2006 [77]
Neural precursors Quinolinic acid (QA)-induced Huntington's 
disease (HD) model in rats
Song et al., 2007 [78]
Pancreatic cells Streptozotocin-treated diabetic mice Shim et al., 2007 [79]
Skeletal myoblasts SCID/Beige mice Barberi et al., 2007 [80]
Neuroepithelial precursors and Dopaminergic 
neurons
Parkinsons disease rodent model Sonntag et al., 2007 [81] Ben-Hur et al., 2004 
[82]
hESCs Open neural tube defect (ONTD) model in 
chick embryos
Lee et al., 2006 [83]
T lymphoid lineage Engraftment into human thymic tissues in 
immunodeficient mice
Galic et al., 2006 [84]Journal of Translational Medicine 2008, 6:7 http://www.translational-medicine.com/content/6/1/7
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to make the cell lines more suitable for clinical applica-
tions.
Despite the drawbacks and debates, an internet search
shows some commercial sources offering embryonic stem
cell therapy, like the Embryonic Tissues Center, in the
Ukraine; Nu Tech Mediworld, in India; and Medra Inc., in
the Dominican Republic. However, as there are no peer
reviewed publications on Medline from these groups,
nothing is known about how they prepare the cells, how
the safety and side effects are evaluated, and how credible
their claims are. There is a need to increase public aware-
ness and to manage the public expectations for hESC
based therapies. The ESC research programs being under-
taken by corporations such as Geron Corporation, CA,
USA, Advanced Cell Technology, CA, USA pave the way
for better planned and transparent procedures employed
embryonic stem cell therapy [64,65]. However, extensive
research is still required to streamline hESC differentia-
tion and develop cell transplantation methodologies. The
recent reports of reprogrammed adult cells yielding the
induced pluripotent cells may put an end to the ethical
debates over the use of human oocytes to create stem cells
[12,66]. Also the derivation of embryonic stem cell lines
that are "HLA-homozygous," now provides avenues to
overcome the problem of immune rejection and may pave
way to utilize ESCs as therapeutics [67]. Trivedi et al.,
(2006) has reported a unique technique for tolerance
induction using nuclear transfer (NT)-hESC-induced
hematopoietic chimerism with synergistic use of adult
bone marrow [68]. This nuclear transfer (NT)-hESC line
was derived by transferring a donor cumulus cell into an
enucleated oocyte, and subjected to electrical fusion fol-
lowed by culture for 5 days. Although these reports are
very promising a great deal of preclinical research still
needs to be undertaken before the envisioned therapeutic
potential of ESCs can be translated to the bedside. With
more number of countries involving themselves in
human ESC research it is expected that the progress will be
faster and the technology may be brought to a clinical
platform sooner than we may predict.
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